"I am a woman and I am a world-class athlete.
The IAAF (International Association of Athletics Federations)
will not drug me or stop me from being who I am," the
28-year-old South African said in a statement after lodging the
appeal.
In a case splitting opinion in women's sport, Semenya lost an
appeal to the Court of Arbitration for Sport (CAS) on May 1
which ruled the IAAF's rules were necessary for athletes with
differences in sexual development (DSDs) to ensure fair
competition.
Semenya's statement added that she will ask the Swiss Federal
Supreme Court to set aside CAS's decision in its entirety, which
it said did not consider medical protocols and uncertain health
consequences of taking testosterone-reducing medication.
Under the new regulations, female athletes with high natural
levels of testosterone wishing to compete in events from 400
meters to a mile must medically limit that level to under five
nmol/L, double the normal female range of below two nmol/L.
Semenya has repeatedly stated she will not take medication to
comply with the regulations, which came into effect on May 8,
but she has also vowed to continue to compete in the 800 meters.
Testosterone is a hormone that increases muscle mass, strength
and hemoglobin - which affects endurance.
Semenya won her last competitive 800 meter race at a Diamond
League meeting in Doha on May 3 and has pledged to return to
Qatar to defend her world title in September, but the
regulations will not allow her to compete unless she takes
medication.
Semenya, who also races 5,000 meters, could continue to compete
in longer distances not affected by the rule change but she has
vowed to continue her fight to stay competing in the 800 meters,
which she recently said was her calling.
(Reporting by Richard Martin; Editing by Ed Osmond and Andrew
Cawthorne)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|